Physician profile
Muhammad Usman
NPI 1396965513
$795.75
in general payments reported to CMS, 2019-2025
10 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.25 · 2022: $18.57 · 2023: $225 · 2024: $281 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $408.75 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $104.74 | 2022-2024 | Shingrix, Arexvy, Bexsero |
| Novo Nordisk INC | $70.86 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $55.31 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $45.31 | 2025 | |
| Dexcom, INC. | $41.91 | 2024-2025 | Dexcom G6 Transmitter |
| Globus Medical, INC. | $22.72 | 2025 | Senza |
| Ibsa Pharma INC. | $20.71 | 2025 | Flector, Licart, Tirosint |
| Currax Pharmaceuticals LLC | $14.19 | 2025 | Contrave |
| Amarin Pharma, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Usman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.